CINDU

News

Novartis is set to expand the label for its oral BTK inhibitor Rhapsido, keeping the drug on course to become one of its biggest-ever brands.

News

AbbVie's bid to bring a rapid and shorter-acting botulinum toxin product to the US market has been knocked back by the FDA.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.